Singapore markets closed
  • Straits Times Index

    3,203.82
    -14.35 (-0.45%)
     
  • S&P 500

    4,551.68
    -23.11 (-0.51%)
     
  • Dow

    35,490.69
    -266.19 (-0.74%)
     
  • Nasdaq

    15,235.84
    +0.12 (+0.00%)
     
  • BTC-USD

    61,121.91
    +2,150.64 (+3.65%)
     
  • CMC Crypto 200

    1,469.04
    -5.29 (-0.36%)
     
  • FTSE 100

    7,241.17
    -12.10 (-0.17%)
     
  • Gold

    1,801.00
    +2.20 (+0.12%)
     
  • Crude Oil

    81.12
    -1.54 (-1.86%)
     
  • 10-Yr Bond

    1.5290
    0.0000 (0.00%)
     
  • Nikkei

    28,820.09
    -278.15 (-0.96%)
     
  • Hang Seng

    25,555.73
    -73.01 (-0.28%)
     
  • FTSE Bursa Malaysia

    1,566.86
    -16.22 (-1.02%)
     
  • Jakarta Composite Index

    6,524.08
    -78.13 (-1.18%)
     
  • PSE Index

    7,157.73
    -72.42 (-1.00%)
     

Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MONROVIA, Calif., September 20, 2021--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. ET / 1:00 p.m. PT.

A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005829/en/

Contacts

Charles Liles
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting